3 Biotech Stocks To Watch This Month
Over the last year, the NASDAQ Biotechnology Index (NBI) has gained nearly 12%, while the iShares NASDAQ Biotech EFT (IBB) increased more than 12% and the SPDR S&P Biotech ETF (XBI) over 22%. The biotechnology sector has is known for being one of the most exciting sectors in the markets, with the potential to generate immense profits practically overnight.
Last year, U.S. drug approvals hit highs not seen over the last two decades, 46 novel medications got the green light from the FDA that were mostly in rare diseases and cancer sub-types, compared less than half of that the year prior. With the increased lifespans of the aging population, demand for medications and treatments is only going to heighten.
The momentum that the industry has seen is what has gained investors’ attention, which has now turned to what’s to come as the sector continues gain and biotech stocks continue to reach new highs.
Biotech Stocks That Hit Fresh 52-Week Highs Sept. 7, 2018:
- Amgen, Inc. (AMGN)
- BioSpecifics Technologies Corp. (BSTC)
- BIO-TECHNE Corp (TECH)
- Eli Lilly And Co (LLY)
- Genomic Health, Inc. (GHDX)
- Kiniksa Pharmaceuticals Ltd (KNSA)
- Krystal Biotech Inc (KRYS)
- Merck & Co., Inc. (MRK)
- Myokardia Inc (MYOK)
- PRA Health Sciences Inc (PRAH)
- ProQR Therapeutics NV (PRQR)
- Rocket Pharmaceuticals Inc (RCKT)
- STRATA Skin Sciences Inc (SSKN)
- Tactile Systems Technology Inc (TCMD)
Many investors habitually place their bets on large-cap stocks, as they may come with a bit of security and liquidity. However, the number of shares that investors can acquire for the most part may be limited, given the higher share prices of these stocks. Numerous investors often seek out lower-priced stocks as a way to not only get a larger position but also for the potential to generate some good returns. Here are a three clinical stage companies to consider adding to your portfolio.